atezolizumab (Tecentriq)

following a full submission assessed under the end of life process:

atezolizumab (Tecentriq®) is accepted for use within NHSScotland.

Indication under review: in combination with bevacizumab for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

In a phase III study in patients with advanced or unresectable HCC who had not received prior systemic therapy, atezolizumab plus bevacizumab was associated with greater overall and progression-free survival compared with a multikinase inhibitor.

This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.